Brief

"On February 05, 2025, the Food and Drug Administration (FDA) issued an update regarding FDA Alerts Patients of Potential to Miss Critical Safety Alerts Due to Phone Settings When Using Smartphone-Compatible Diabetes Devices. The FDA has received reports that critical safety alerts from diabetes devices connected to smartphones may not be delivered or heard, potentially leading to serious harm, including severe hypoglycemia, hyperglycemia, and death."

For Immediate Release:
February 05, 2025

Today, the U.S. Food and Drug Administration is alerting patients of a safety concern regarding diabetes devices, such as continuous glucose monitors (CGMs), insulin pumps and automated insulin dosing systems, that rely on a smartphone to deliver critical safety alerts. Users of these smartphone-compatible diabetes devices can configure alert settings, such as which alerts to receive, how often and how the alerts are delivered (e.g. audible, vibration, text only) through the app on their phone.The FDA has received medical device reports in which users report these alerts are not being delivered or not being heard, in cases where the users thought they had configured the alerts to be delivered. In some cases, missing these alerts may have contributed to serious harm, including severe hypoglycemia (low blood sugar), severe hyperglycemia (high blood sugar), diabetic ketoacidosis (when the body does not have enough insulin to use blood sugar for energy) and death.“Modern medical devices, such as diabetes devices that connect to a smartphone, can provide users with the convenience and flexibility to configure alerts that are personalized to them. However, users should stay aware of alert settings and monitor these devices to ensure they continue to receive critical alerts as expected,” said Courtney Lias, director of the Office of In Vitro Diagnostic Products in the FDA’s Center for Devices and Radiological Health. “Even if configured correctly, certain hardware or software changes can interrupt the expected operation of these critical devices, which can lead to patient harm if undetected.”The FDA has identified, among others, the following hardware and software changes, updates and configurations that may lead to critical alerts not being received as expected:software configuration issues, such as app notification permissions, using “do not disturb” or “focus mode” or the app entering “deep sleep” after a period of not being used;connecting new hardware to the smartphone, such as connecting to car audio or using wireless earphones, that can change the default volume of alerts or prevent delivery of alerts; andsmartphone operating system updates that are not supported by the medical device application.The FDA’s safety communication provides recommendations, such as the following, for users of these devices:Carefully follow the instructions provided by diabetes device manufacturers when installing, setting up or updating mobile medical apps on the smartphone;turn off automatic operating system (OS) updates to the smartphone and do not update the phone’s OS until confirming the diabetes device app is compatible with the new OS version;after updating the phone’s OS or adding a new accessory, such as wireless headphones, confirm alert settings then carefully monitor the medical device app to make sure alerts are received and can be heard as expected;at least once a month, check that the smartphone alerts are configured as expected;if alerts are not being received as expected from the mobile medical app, or cannot be heard, call the technical support number for the medical device for assistance; andreport any problems with the diabetes device to the FDA.The FDA is working with diabetes-related medical device manufacturers to ensure that smartphone alert configurations of their devices are carefully evaluated prior to use by patients. The agency is also working with manufacturers to ensure that settings in smartphones and mobile medical apps that may impact safety alerts are continuously tested and any updates to recommended configurations are communicated quickly and clearly to users.
Related Information

Related Information
Safety Communication: Potential to Miss Critical Safety Alerts for Smartphone-Compatible Diabetes Devices

###

Boilerplate
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.

Inquiries

Media:

Jim McKinney

(240) 367-5380

Consumer:
888-INFO-FDA

Highlights content goes here...

Purpose
The U.S. Food and Drug Administration has issued a safety alert regarding diabetes devices, such as continuous glucose monitors (CGMs), insulin pumps, and automated insulin dosing systems, that rely on smartphones to deliver critical safety alerts. The FDA is cautioning patients about potential safety risks associated with these devices.

Effects on Industry
The FDA’s safety communication may have significant implications for the medical device industry, particularly manufacturers of diabetes-related devices that connect to smartphones. Companies in this sector may need to reevaluate their products’ alert settings and ensure that they are properly configured to prevent critical alerts from being missed. This update may also lead to changes in the way these devices are designed and marketed.

Relevant Stakeholders
Patients who use smartphone-compatible diabetes devices, medical device manufacturers, healthcare providers, and regulatory agencies such as the FDA are all relevant stakeholders affected by this safety alert. Patients should be aware of potential risks associated with their devices and take steps to ensure they receive critical alerts as expected. Manufacturers must also work with the FDA to address these concerns.

Next Steps
To mitigate potential harm from missed critical alerts, patients using smartphone-compatible diabetes devices should carefully follow manufacturer instructions when setting up or updating mobile medical apps on their smartphones. They should also regularly check that alert settings are configured correctly and contact technical support if issues arise. Manufacturers must ensure that their products’ alert settings are properly evaluated prior to use by patients and communicate any necessary updates to users.

Any Other Relevant Information
The FDA is actively working with diabetes-related medical device manufacturers to address these concerns and ensure the safety of patients using these devices. The agency is also collaborating with manufacturers to develop strategies for testing and communicating changes to recommended configurations, which will be communicated quickly and clearly to users.

Food and Drug Administration (FDA)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies